CONDENSED CONSOLIDATED GUARANTOR FINANCIAL INFORMATION (Tables) (Predecessor)

6 Months Ended

Jun. 30, 2012

Predecessor

Condensed consolidated guarantor financial information

Schedule of Condensed Consolidating Balance Sheet

Condensed Consolidating Balance Sheet

As at June 30, 2012

USD (in ‘000s)

	Successor Company
	Parent Company
	Angiotech
	Pharmaceuticals,		Guarantor		Non Guarantor		Consolidating			Consolidated
	Inc.		Subsidiaries		Subsidiaries		Adjustments			Total
ASSETS
Current assets
Cash and cash equivalents	$	20,797	$	27,648	$	9,546	$	—		$	57,991
Short term investments	644		—		—		—			644
Accounts receivable	—		21,077		9,342		—			30,419
Income taxes receivable	—		36		488		—			524
Inventories	—		31,631		6,548		—			38,179
Deferred income taxes, current portion	—		6,026		—		—			6,026
Deferred financing costs, current portion	—		434		—		—			434
Prepaid expenses and other current assets	1,345		1,065		563		—			2,973
Total Current Assets	22,786		87,917		26,487		—			137,190
Investment in subsidiaries	401,721		19,377		—		(421,098		)	—
Property, plant and equipment	1,603		26,616		7,208		—			35,427
Intangible assets	68,821		243,431		14,729		—			326,981
Goodwill	—		101,245		21,997		—			123,242
Deferred income taxes	1,828		738		—		—			2,566
Deferred financing costs, non-current portion	—		300		—		—			300
Other assets	80		6		224		—			310
Total Assets	496,839		479,630		70,645		(421,098		)	626,016
LIABILITIES AND SHAREHOLDERS’ (DEFICIT) EQUITY
Current liabilities
Accounts payable and accrued liabilities	5,111		15,615		4,932		—			25,658
Income taxes payable	574		2,500		2,584		—			5,658
Interest payable on long-term debt	1,406		—		—		—			1,406
Deferred revenue, current portion	4,846		1,359		—		—			6,205
Revolving credit facility	—		—		—		—			—
Total Current Liabilities	11,937		19,474		7,516		—			38,927
Deferred revenue	13,966		3,641		462		—			18,069
Deferred income taxes	—		89,697		4,589		—			94,286
Other tax liabilities	2,320		1,549		2,249		—			6,118
Debt	325,000		—		—		—			325,000
Other liabilities
Total Non-current Liabilities	341,286		94,887		7,300		—			443,473
Total Shareholders’ (Deficit) Equity	143,616		365,269		55,829		(421,098		)	143,616
Total Liabilities and Shareholders’ (Deficit) Equity	$	496,839	$	479,630	$	70,645	$	(421,098	)	$	626,016

Condensed Consolidating Balance Sheet

As at December 31, 2011

USD (in ‘000s)

	Successor Company
	Parent Company
	Angiotech
	Pharmaceuticals,		Guarantor		Non Guarantor		Consolidating			Consolidated
	Inc.		Subsidiaries		Subsidiaries		Adjustments			Total
ASSETS
Current assets
Cash and cash equivalents	$	8,649	$	7,449	$	6,075	$	—		$	22,173
Short term investments	3,259		—		—		—			3,259
Accounts receivable	167		20,076		7,995		—			28,238
Income taxes receivable	—		1,239		223		—			1,462
Inventories	—		26,744		7,560		—			34,304
Deferred income taxes	—		3,995		—		—			3,995
Prepaid expenses and other current assets	1,120		1,541		506		—			3,167
Total Current Assets	13,195		61,044		22,359		—			96,598
Investment in subsidiaries	388,653		20,538		—		(409,191		)	—
Assets held for sale	—		—		—		—			—
Property, plant and equipment	3,213		22,552		13,424		—			39,189
Intangible assets	75,754		251,905		15,407		—			343,066
Goodwill	—		101,244		21,984		—			123,228
Deferred income taxes	1,729		—		436		—			2,165
Other assets	3,537		54		269		—			3,860
Total Assets	486,081		457,337		73,879		(409,191		)	608,106
LIABILITIES AND SHAREHOLDERS’ (DEFICIT) EQUITY
Current liabilities
Accounts payable and accrued liabilities		6,999		17,896		5,642		—			30,537
Income taxes payable	—		—		2,023		—			2,023
Interest payable on long-term debt	1,450		—		—		—			1,450
Deferred revenue, current portion	496		—		—		—			496
Revolving credit facility	—		40		—		—			40
Debt	—		—		—		—			—
Total Current Liabilities	8,945		17,936		7,665		—			34,546
Deferred leasehold inducement	—		—		—		—			—
Deferred revenue	3,456		—		315		—			3,771
Deferred income taxes	—		87,415		5,219		—			92,634
Other tax liabilities	2,273		896		2,560		—			5,729
Debt	325,000		—		—		—			325,000
Other liabilities	—		19		—		—			19
Total Non-current Liabilities	330,729		88,330		8,094		—			427,153
Total Shareholders’ (Deficit) Equity	146,407		351,071		58,120		(409,191		)	146,407
Total Liabilities and Shareholders’ (Deficit) Equity	$	486,081	$	457,337	$	73,879	$	(409,191	)	$	608,106

Schedule of Condensed Consolidated Statement of Operations

Condensed Consolidated Statement of Operations

Three months ended June 30, 2012

USD (in ‘000s)

	Successor Company
	Parent Company
	Angiotech
	Pharmaceuticals,			Guarantors			Non Guarantors		Consolidating			Consolidated
	Inc.			Subsidiaries			Subsidiaries		Adjustments			Total
REVENUE
Product sales, net	$	—		$	40,704		$	19,274	$	(3,455	)	$	56,523
Royalty revenue	4,051			753			—		—			4,804
License fees	—			—			11		—			11
	4,051			41,457			19,285		(3,455		)	61,338
EXPENSES
Cost of products sold	—			17,080			12,262		(2,020		)	27,322
License and royalty fees	63			—			—		—			63
Research & development	389			1,996			38		—			2,423
Selling, general and administration	2,851			12,329			2,604		—			17,784
Depreciation and amortization	3,819			4,367			242		—			8,428
Write-down of assets held for sale	—			—			—		—			—
Write-down of property, plant and equipment	692			—			—		—			692
Write-down of intangible assets	—			—			—		—			—
	7,814			35,772			15,146		(2,020		)	56,712
Operating income (loss)	(3,763		)	5,685			4,139		(1,435		)	4,626
Other income (expense)
Foreign exchange gain (loss)	123			12			79		—			214
Other (expense) income	4			236			—		—			240
Interest expense	(4,108		)	(198		)	—		—			(4,306		)
Impairments and realized losses on investments	(68		)	—			—		—			(68		)
Total other expenses	(4,049		)	50			79		—			(3,920		)
Income (loss) before income tax expense (recovery)	(7,812		)	5,735			4,218		(1,435		)	706
Income tax expense (recovery)	95			2,449			1,110		—			3,654
Income (loss) from operations	(7,907		)	3,286			3,108		(1,435		)	(2,948		)
Equity in subsidiaries	4,959			3,621					(8,580		)	—
Net income (loss)	$	(2,948	)	$	6,907		$	3,108	$	(10,015	)	$	(2,948	)

Condensed Consolidated Statement of Operations

For the two months ended June 30, 2011

USD (in ‘000s)

	Successor Company
	Parent Company Angiotech Pharmaceuticals, Inc.			Guarantors Subsidiaries			Non Guarantors Subsidiaries			Consolidating Adjustments			Consolidated Total
REVENUE
Product sales, net	$	7		$	26,341		$	12,284		$	(2,730	)	$	35,902
Royalty revenue	94			974			—			—			1,068
	101			27,315			12,284			(2,730		)	36,970
EXPENSES
Cost of products sold	—			18,065			10,446			(1,577		)	26,934
License and royalty fees	50			—			—			—			50
Research & development	1,216			1,517			96			—			2,829
Selling, general and administration	1,730			9,267			1,784			—			12,781
Depreciation and amortization	2,466			2,933			291			—			5,690
	5,462			31,782			12,617			(1,577		)	48,284
Operating income (loss)	(5,361		)	(4,467		)	(333		)	(1,153		)	(11,314		)
Other income (expense)
Foreign exchange gain (loss)	172			24			296			—			492
Other (expense) income	652			(2,696		)	2,156			—			112
Interest expense	(2,784		)	(235		)	(13		)	—			(3,032		)
Total other expenses	(1,960		)	(2,907		)	2,439			—			(2,428		)
(Loss) income before income tax expense	(7,321		)	(7,374		)	2,106			(1,153		)	(13,742		)
Income tax (recovery) expense	509			(774		)	771			—			506
(Loss) income from operations	(7,830		)	(6,600		)	1,335			(1,153		)	(14,248		)
Equity in subsidiaries	(6,418		)	1,286			—			5,132			—
Net income (loss)	$	(14,248	)	$	(5,314	)	$	1,335		$	3,979		$	(14,248	)

Condensed Consolidated Statement of Operations

For the one month ended April 30, 2011

USD (in ‘000s)

	Predecessor Company
	Parent Company Angiotech Pharmaceuticals, Inc.			Guarantors Subsidiaries			Non Guarantors Subsidiaries			Consolidating Adjustments			Consolidated Total
REVENUE
Product sales, net	$	3		$	15,222		$	5,617		$	(4,477	)	$	16,365
Royalty revenue	5,238			47			—			—			5,285
License fees	—			—			24			—			24
	5,241			15,269			5,641			(4,477		)	21,674
EXPENSES
Cost of products sold	—			7,433			3,387			(2,529		)	8,291
Research & development	583			522			51			—			1,156
Selling, general and administration	1,672			3,646			873			—			6,191
Depreciation and amortization	808			2,205			75			—			3,088
Write-down of assets held for sale	570			—			—			—			570
	3,633			13,806			4,386			(2,529		)	19,296
Operating income (loss)	1,608			1,463			1,255			(1,948		)	2,378
Other income (expense)
Foreign exchange gain (loss)	(242		)	42			(166		)	—			(366		)
Other (expense) income	2			(5		)	13			—			10
Interest expense	(1,210		)	(996		)	(11		)	—			(2,217		)
Total other expenses	(1,450		)	(959		)	(164		)	—			(2,573		)
Income (loss) before reorganization items and income tax expense	158			504			1,091			(1,948		)	(195		)
Reorganization items	89,011			216,567			24,248			—			329,826
Gain on extinguishment of debt and settlement of other liabilities	67,307			—			—			—			67,307
Income (loss) before income taxes	156,476			217,071			25,339			(1,948		)	396,938
Income tax (recovery) expense	(111		)	(685		)	215			—			(581		)
Income (loss) from operations	156,587			217,756			25,124			(1,948		)	397,519
Equity in subsidiaries	119			414			—			(533		)	—
Net income (loss)	$	156,706		$	218,170		$	25,124		$	(2,481	)	$	397,519

Condensed Consolidated Statement of Operations

Six months ended June 30, 2012

USD (in ‘000s)

	Successor Company
	Parent Company
	Angiotech
	Pharmaceuticals,			Guarantors			Non Guarantors			Consolidating			Consolidated
	Inc.			Subsidiaries			Subsidiaries			Adjustments			Total
REVENUE
Product sales, net	$	—		$	79,304		$	38,884		$	(7,041	)	$	111,147
Royalty revenue	9,187			1,535			—			—			10,722
License fees	—			—			20			—			20
	9,187			80,839			38,904			(7,041		)	121,889
EXPENSES
Cost of products sold	—			30,964			25,163			(4,121		)	52,006
License and royalty fees	174			—			—			—			174
Research & development	813			3,455			140			—			4,408
Selling, general and administration	5,381			24,851			5,199			—			35,431
Depreciation and amortization	7,795			8,972			684			—			17,451
Write-down of assets held for sale	—			—			—			—			—
Write-down of property, plant and equipment	692			173			—			—			865
Write-down of intangible assets	—			—			—			—			—
	14,855			68,415			31,186			(4,121		)	110,335
Operating income (loss)	(5,668		)	12,424			7,718			(2,920		)	11,554
Other income (expense)
Foreign exchange gain (loss)	(11		)	(16		)	(29		)	—			(56		)
Other (expense) income	596			306			—			—			902
Interest expense	(8,216		)	(342		)	—			—			(8,558		)
Impairments and realized losses on investments	(349		)	—			—			—			(349		)
Total other expenses	(7,980		)	(52		)	(29		)	—			(8,061		)
Income (loss) before income tax expense (recovery)	(13,648		)	12,372			7,689			(2,920		)	3,493
Income tax expense (recovery)	(41		)	4,074			2,407			—			6,440
Income (loss) from operations	(13,607		)	8,298			5,282			(2,920		)	(2,947		)
Equity in subsidiaries	10,660			6,536			—			(17,196		)	—
Net income (loss)	$	(2,947	)	$	14,834		$	5,282		$	(20,116	)	$	(2,947	)

Condensed Consolidated Statement of Operations

For the four months ended April 30, 2011

USD (in ‘000s)

	Predecessor Company
	Parent CompanyAngiotechPharmaceuticals,Inc.			GuarantorsSubsidiaries			Non GuarantorsSubsidiaries			ConsolidatingAdjustments			ConsolidatedTotal
REVENUE
Product sales, net	$	8		$	54,494		$	22,832		$	(8,136	)	$	69,198
Royalty revenue	9,930			1,011			—			—			10,941
License fees	—			—			127			—			127
	9,938			55,505			22,959			(8,136		)	80,266
EXPENSES
Cost of products sold	—			22,041			14,783			(4,605		)	32,219
License and royalty fees	68			—			—			—			68
Research & development	2,448			3,022			216			—			5,686
Selling, general and administration	3,187			18,198			3,461			—			24,846
Depreciation and amortization	3,007			11,021			301			—			14,329
Write-down of assets held for sale	570			—			—			—			570
Write-down of property, plant and equipment	—			215			—			—			215
	9,280			54,497			18,761			(4,605		)	77,933
Operating income (loss)	658			1,008			4,198			(3,531		)	2,333
Other income (expense)
Foreign exchange gain (loss)	(492		)	(46		)	(108		)	—			(646		)
Other (expense) income	1,116			(1,134		)	52			—			34
Interest expense on long-term debt	(7,372		)	(2,914		)	(41		)	—			(10,327		)
Total other expenses	(6,748		)	(4,094		)	(97		)	—			(10,939		)
Loss before reorganization items and income tax expense	(6,090		)	(3,086		)	4,101			(3,531		)	(8,606		)
Reorganization items	81,377			215,409			24,248			—			321,084
Gain on extinguishment of debt and settlement of other liabilities	67,307			—			—			—			67,307
Income (loss) before income tax	142,594			212,373			28,349			(3,531		)	379,785
Income tax (recovery) expense	(197		)	(910		)	1,374			—			267
Income (loss) from operations	142,791			213,383			26,975			(3,531		)	379,518
Equity in subsidiaries	(4,086		)	2,502			—			1,584			—
Net income (loss)	$	138,705		$	215,785		$	26,975		$	(1,947	)	$	379,518

Schedule of Condensed Consolidated Statement of Cash Flows

Condensed Consolidated Statement of Cash Flows

For the three months ended June 30, 2012

USD (in ‘000s)

	Successor Company
	Parent Company
	Angiotech
	Pharmaceuticals,			Guarantors			Non Guarantors			Consolidating		Consolidated
	Inc.			Subsidiaries			Subsidiaries			Adjustments		Total
OPERATING ACTIVITIES:
Cash used in operating activities before reorg items	$	12,181		$	6,430		$	4,750		$	—	$	23,361
OPERATING CASH FLOWS FROM REORGANIZATION ACTIVITIES
Professional fess paid for services rendered in connection with the Creditor Protection Proceedings	—			—			—			—		—
Key Employment Incentive Plan fee	—			—			—			—		—
Cash used in reorganization activities	—			—			—			—		—
Cash used in operating activites	12,181			6,430			4,750			—		23,361
INVESTING ACTIVITIES:
Purchase of property, plant and equipment	(37		)	(335		)	(64		)	—		(436		)
Proceeds from disposition of property, plant and equipment	—			400			—			—		400
Proceeds from disposition of short term investments	1,150			—			—			—		1,150
Cash used in investing activities	1,113			65			(64		)	—		1,114
FINANCING ACTIVITIES:
Share capital issued	(881		)	—			—			—		(881		)
Deferred financing charges and costs	—			(474		)	—			—		(474		)
Dividends received / (paid)	—			1,500			(1,500		)	—		—
Advances on Revolving Credit Facility	—			—			—			—		—
Repayments on revolving Credit Facility	—			—			—			—		—
Intercompany notes payable/receivable	325			(325		)	—			—		—
Cash (used in) provided by financing activities	(556		)	701			(1,500		)	—		(1,355		)
Effect of exchange rate changes on cash and cash equivalents	—			—			(202		)	—		(202		)
Net (decrease) increase in cash and cash equivalents	12,738			7,196			2,984			—		22,918
Cash and cash equivalents, beginning of period	8,059			20,452			6,562			—		35,073
Cash and cash equivalents, end of period	$	20,797		$	27,648		$	9,546				$	57,991

Condensed Consolidated Statement of Cash Flows

For the two month ended June 30, 2011

USD (in ‘000s)

	Successor Company
	Parent Company Angiotech Pharmaceuticals, Inc.			Guarantors Subsidiaries			Non Guarantors Subsidiaries			Consolidating Adjustments		Consolidated Total
OPERATING ACTIVITIES:
Cash used in operating activities before reorg items	$	(2,826	)	$	7,012		$	2,313		$	—	$	6,499
OPERATING CASH FLOWS FROM REORGANIZATION ACTIVITIES
Professional fees paid for services rendered in connection with the Creditor Protection Proceedings	(8,105		)	—			—			—		(8,105		)
Key Employment Incentive Plan fee	(156		)	(395		)	—			—		(551		)
Cash used in reorganization activities	(8,261		)	(395		)	—			—		(8,656		)
Cash used in operating activities	(11,087		)	6,617			2,313			—		(2,157		)
INVESTING ACTIVITIES:
Purchase of property, plant and equipment	(97		)	(288		)	—			—		(385		)
Proceeds from disposition of property, plant and equipment	1,732			892			—			—		2,624
Cash used in investing activities	1,635			604			—			—		2,239
FINANCING ACTIVITIES:
Dividends received / (paid)	—			1,500			(1,500		)	—		—
Net (repayments) advances on Revolving Credit Facility	—			(7,542		)	—			—		(7,542		)
Intercompany notes payable/receivable	10,826			(10,826		)				—		—
Cash provided by (used in) financing activities before reorganization activities	10,826			(16,868		)	(1,500		)	—		(7,542		)
FINANCING CASH FLOWS FROM REORGANIZATION ACTIVITIES
Deferred financing costs	(1,408		)	—			—			—		(1,408		)
Cash provided by (used in) financing activities	9,418			(16,868		)	(1,500		)	—		(8,950		)
Effect of exchange rate changes on cash and cash equivalents	—			—			283			—		283
Net (decrease) increase in cash and cash equivalents	(34		)	(9,647		)	1,096			—		(8,585		)
Cash and cash equivalents, beginning of period	5,090			18,132			7,000			—		30,222
Cash and cash equivalents, end of period	$	5,056		$	8,485		$	8,096		$	—	$	21,637

Condensed Consolidated Statement of Cash Flows

For the one month ended April 30, 2011

USD (in ‘000s)

	Predecessor Company
	Parent Company Angiotech Pharmaceuticals, Inc.			Guarantors Subsidiaries			Non Guarantors Subsidiaries			Consolidating Adjustments		Consolidated Total
OPERATING ACTIVITIES:
Cash used in operating activities before reorg items	$	(998	)	$	288		$	2,516		$	—	$	1,806
OPERATING CASH FLOWS FROM REORGANIZATION ACTIVITIES
Professional fees paid for services rendered in connection with the Creditor
Protection Proceedings	(3,095		)	—			—			—		(3,095		)
Key Employment Incentive Plan fee	—			—			—			—		—
Director’s and officer’s insurance	—			—			—			—		—
Cash used in reorganization activities	(3,095		)	—			—			—		(3,095		)
Cash used in operating activities	(4,093		)	288			2,516			—		(1,289		)
INVESTING ACTIVITIES:
Purchase of property, plant and equipment	(29		)	(113		)	—			—		(142		)
Proceeds from disposition of property, plant and equipment	—			—			—			—		—
Loans advanced	—			—			—			—		—
Asset acquisition costs	—			—			—			—		—
Cash used in investing activities	(29		)	(113		)	—			—		(142		)
FINANCING ACTIVITIES:
Share capital issued	—			—			—			—		—
Deferred financing charges and costs	—			(50		)	—			—		(50		)
Dividends received / (paid)	—			2,137			(2,137		)	—		—
Net (repayments) advances on Revolving Credit Facility	—			5,000			—			—		5,000
Proceeds from stock options exercised	—			—			—			—		—
Intercompany notes payable/receivable	3,789			(3,789		)				—		—
Cash provided by (used in) financing activities	3,789			3,298			(2,137		)	—		4,950
Effect of exchange rate changes on cash and cash equivalents	—			—			(208		)	—		(208		)
Net (decrease) increase in cash and cash equivalents	(333		)	3,473			171			—		3,311
Cash and cash equivalents, beginning of period	5,423			14,659			6,829			—		26,911
Cash and cash equivalents, end of period	$	5,090		$	18,132		$	7,000		$	—	$	30,222

Condensed Consolidated Statement of Cash Flows

For the six months ended June 30, 2012

USD (in ‘000s)

	Successor Company
	Parent Company
	Angiotech
	Pharmaceuticals,			Guarantors			Non Guarantors			Consolidating		Consolidated
	Inc.			Subsidiaries			Subsidiaries			Adjustments		Total
OPERATING ACTIVITIES:
Cash used in operating activities before reorg items	$	12,000		$	16,568		$	6,663		$	—	$	35,231
OPERATING CASH FLOWS FROM REORGANIZATION ACTIVITIES
Professional fess paid for services rendered in connection with the Creditor Protection Proceedings	—			—			—			—		—
Key Employment Incentive Plan fee	—			—			—			—		—
Cash used in reorganization activities	—			—			—			—		—
Cash used in operating activites	12,000			16,568			6,663			—		35,231
INVESTING ACTIVITIES:
Purchase of property, plant and equipment	(56		)	(669		)	(124		)	—		(849		)
Proceeds from disposition of property, plant and equipment	576			400			—			—		976
Proceeds from disposition of short term investments	2,272			—			—			—		2,272
Cash used in investing activities	2,792			(269		)	(124		)	—		2,399
FINANCING ACTIVITIES:
Share capital issued	(881		)	—			—			—		(881		)
Deferred financing charges and costs	—			(824		)	—			—		(824		)
Dividends received / (paid)	—			3,000			(3,000		)	—		—
Advances on Revolving Credit Facility	—			—			—			—		—
Repayments on revolving Credit Facility	—			(39		)	—			—		(39		)
Intercompany notes payable/receivable	(1,763		)	1,763			—			—		—
Cash (used in) provided by financing activities	(2,644		)	3,900			(3,000		)	—		(1,744		)
Effect of exchange rate changes on cash and cash equivalents	—			—			(68		)	—		(68		)
Net (decrease) increase in cash and cash equivalents	12,148			20,199			3,471			—		35,818
Cash and cash equivalents, beginning of period	8,649			7,449			6,075			—		22,173
Cash and cash equivalents, end of period	$	20,797		$	27,648		$	9,546		$	—	$	57,991

Condensed Consolidated Statement of Cash Flows

For the four months ended April 30, 2011

USD (in ‘000s)

	Predecessor Company
	Parent Company Angiotech Pharmaceuticals, Inc.			Guarantors Subsidiaries			Non Guarantors Subsidiaries			Consolidating Adjustments		Consolidated Total
OPERATING ACTIVITIES:
Cash used in operating activities before reorg items	$	(7,900	)	$	2,887		$	3,593		$	—	$	(1,420	)
OPERATING CASH FLOWS FROM REORGANIZATION ACTIVITIES
Professional fees paid for services rendered in connection with the Creditor
Protection Proceedings	(7,447		)	(2,608		)	—			—		(10,055		)
Key Employment Incentive Plan fee	—			—			—			—		—
Director’s and officer’s insurance	(1,382		)	—			—			—		(1,382		)
Cash used in reorganization activities	(8,829		)	(2,608		)	—			—		(11,437		)
Cash used in operating activities	(16,729		)	279			3,593			—		(12,857		)
INVESTING ACTIVITIES:
Purchase of property, plant and equipment	(329		)	(591		)	(25		)	—		(945		)
Cash used in investing activities	(329		)	(591		)	(25		)	—		(945		)
FINANCING ACTIVITIES:
Share capital issued	1			—			—			—		1
Deferred financing charges and costs	—			(1,278		)	—			—		(1,278		)
Dividends received / (paid)	—			3,137			(3,137		)	—		—
Net (repayments) advances on Revolving Credit Facility	—			12,018			—			—		12,018
Intercompany notes payable/receivable	10,967			(10,967		)				—		—
Cash provided by (used in) financing activities	10,968			2,910			(3,137		)	—		10,741
Effect of exchange rate changes on cash and cash equivalents	—			—			(32		)	—		(32		)
Net (decrease) increase in cash and cash equivalents	(6,090		)	2,598			399			—		(3,093		)
Cash and cash equivalents, beginning of period	11,180			15,340			6,795			—		33,315
Cash and cash equivalents, end of period	$	5,090		$	18,132		$	7,000		$	—	$	30,222